Cargando…
Glioblastoma: Current Status, Emerging Targets, and Recent Advances
[Image: see text] Glioblastoma (GBM) is a highly malignant brain tumor characterized by a heterogeneous population of genetically unstable and highly infiltrative cells that are resistant to chemotherapy. Although substantial efforts have been invested in the field of anti-GBM drug discovery in the...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Chemical Society
2022
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9297300/ https://www.ncbi.nlm.nih.gov/pubmed/35786935 http://dx.doi.org/10.1021/acs.jmedchem.1c01946 |
_version_ | 1784750447796420608 |
---|---|
author | Thakur, Amandeep Faujdar, Chetna Sharma, Ram Sharma, Sachin Malik, Basant Nepali, Kunal Liou, Jing Ping |
author_facet | Thakur, Amandeep Faujdar, Chetna Sharma, Ram Sharma, Sachin Malik, Basant Nepali, Kunal Liou, Jing Ping |
author_sort | Thakur, Amandeep |
collection | PubMed |
description | [Image: see text] Glioblastoma (GBM) is a highly malignant brain tumor characterized by a heterogeneous population of genetically unstable and highly infiltrative cells that are resistant to chemotherapy. Although substantial efforts have been invested in the field of anti-GBM drug discovery in the past decade, success has primarily been confined to the preclinical level, and clinical studies have often been hampered due to efficacy-, selectivity-, or physicochemical property-related issues. Thus, expansion of the list of molecular targets coupled with a pragmatic design of new small-molecule inhibitors with central nervous system (CNS)-penetrating ability is required to steer the wheels of anti-GBM drug discovery endeavors. This Perspective presents various aspects of drug discovery (challenges in GBM drug discovery and delivery, therapeutic targets, and agents under clinical investigation). The comprehensively covered sections include the recent medicinal chemistry campaigns embarked upon to validate the potential of numerous enzymes/proteins/receptors as therapeutic targets in GBM. |
format | Online Article Text |
id | pubmed-9297300 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | American Chemical Society |
record_format | MEDLINE/PubMed |
spelling | pubmed-92973002022-07-21 Glioblastoma: Current Status, Emerging Targets, and Recent Advances Thakur, Amandeep Faujdar, Chetna Sharma, Ram Sharma, Sachin Malik, Basant Nepali, Kunal Liou, Jing Ping J Med Chem [Image: see text] Glioblastoma (GBM) is a highly malignant brain tumor characterized by a heterogeneous population of genetically unstable and highly infiltrative cells that are resistant to chemotherapy. Although substantial efforts have been invested in the field of anti-GBM drug discovery in the past decade, success has primarily been confined to the preclinical level, and clinical studies have often been hampered due to efficacy-, selectivity-, or physicochemical property-related issues. Thus, expansion of the list of molecular targets coupled with a pragmatic design of new small-molecule inhibitors with central nervous system (CNS)-penetrating ability is required to steer the wheels of anti-GBM drug discovery endeavors. This Perspective presents various aspects of drug discovery (challenges in GBM drug discovery and delivery, therapeutic targets, and agents under clinical investigation). The comprehensively covered sections include the recent medicinal chemistry campaigns embarked upon to validate the potential of numerous enzymes/proteins/receptors as therapeutic targets in GBM. American Chemical Society 2022-07-05 2022-07-14 /pmc/articles/PMC9297300/ /pubmed/35786935 http://dx.doi.org/10.1021/acs.jmedchem.1c01946 Text en © 2022 American Chemical Society https://creativecommons.org/licenses/by/4.0/Permits the broadest form of re-use including for commercial purposes, provided that author attribution and integrity are maintained (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Thakur, Amandeep Faujdar, Chetna Sharma, Ram Sharma, Sachin Malik, Basant Nepali, Kunal Liou, Jing Ping Glioblastoma: Current Status, Emerging Targets, and Recent Advances |
title | Glioblastoma: Current
Status, Emerging Targets, and
Recent Advances |
title_full | Glioblastoma: Current
Status, Emerging Targets, and
Recent Advances |
title_fullStr | Glioblastoma: Current
Status, Emerging Targets, and
Recent Advances |
title_full_unstemmed | Glioblastoma: Current
Status, Emerging Targets, and
Recent Advances |
title_short | Glioblastoma: Current
Status, Emerging Targets, and
Recent Advances |
title_sort | glioblastoma: current
status, emerging targets, and
recent advances |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9297300/ https://www.ncbi.nlm.nih.gov/pubmed/35786935 http://dx.doi.org/10.1021/acs.jmedchem.1c01946 |
work_keys_str_mv | AT thakuramandeep glioblastomacurrentstatusemergingtargetsandrecentadvances AT faujdarchetna glioblastomacurrentstatusemergingtargetsandrecentadvances AT sharmaram glioblastomacurrentstatusemergingtargetsandrecentadvances AT sharmasachin glioblastomacurrentstatusemergingtargetsandrecentadvances AT malikbasant glioblastomacurrentstatusemergingtargetsandrecentadvances AT nepalikunal glioblastomacurrentstatusemergingtargetsandrecentadvances AT lioujingping glioblastomacurrentstatusemergingtargetsandrecentadvances |